Standard treatment of advanced-stage diffuse large B-cell lymphoma
- PMID: 17027655
- DOI: 10.1053/j.seminhematol.2006.07.004
Standard treatment of advanced-stage diffuse large B-cell lymphoma
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoma and is not localized in 70% of the cases. Even if the clinical picture, the morphologic aspect, and the prognostic parameters are different from one patient to another, the standard treatment is the same for all patients. Currently, treatment decision is based on the International Prognostic Index (IPI) and age of the patient. Outcome has been completely modified with the introduction of rituximab in combination with chemotherapy. A review of standard treatment and remaining questions is presented.
Comment in
-
Treatment of diffuse large B-cell lymphomas.Semin Hematol. 2006 Oct;43(4):205-6. doi: 10.1053/j.seminhematol.2006.07.007. Semin Hematol. 2006. PMID: 17027653 No abstract available.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
